Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of $2.75 per share. The offering is expected to close on November 20, 2017.
The WilmerHale deal team representing Achillion includes Steven Singer, Cynthia Mazareas, Scott Lunin and Killian Nolan.